1. PD-022PARP-ness in metastatic colorectal cancer. (2nd July 2019) Authors: Mauri, G; Kanter, K; Fish, M; Horick, N; Allen, J; Blaszkowsky, L; Clark, J; Ryan, D; Nipp, R; Giantonio, B; Goyal, L; Dubois, J; Murphy, J; Roeland, E; Weekes, C; Wo, J; Hong, T; Zhu, A; Van Seventer, E; Corcoran, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SO-003Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. (2nd July 2019) Authors: Matos, I; Goyal, L; Cleary, J; Voss, M; Oh, D; Bernstam, F Meric; Ng, C; Iyer, G; Ishii, N; Hu, Y; Chessex, A Vaslin; Pokorska-Bocci, A; Nicolas, V; Kirpicheva, Y; Zanna, C; Flaherty, K; Tabernero, J; Hyman, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PD-008Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. (2nd July 2019) Authors: Parikh, A; Kanter, K; Mojtahed, A; Schneider, J; Seventer, E Van; Fish, M; Allen, J; Blaszkowsky, L; Wo, J; Clark, J; Giantonio, B; Goyal, L; Hong, T; Nipp, R; Roeland, E; Weekes, C; Zhu, A; Ryan, D; Fetter, I; Horick, N Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. (23rd October 2018) Authors: Javle, M; Kelley, R K; Roychowdhury, S; Weiss, K H; Abou-Alfa, G K; Macarulla, T; Sadeghi, S; Waldschmidt, D; Zhu, A X; Goyal, L; Borad, M; Yong, W P; Borbath, I; El-Khoueiry, A; Philip, P; Moran, S; Ye, Y; Ising, M; Lewis, N; Bekaii-Saab, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. (20th June 2018) Authors: Meric-Bernstam, F; Arkenau, H; Tran, B; Bahleda, R; Kelley, R; Hierro, C; Ahn, D; Zhu, A; Javle, M; Winkler, R; He, H; Huang, J; Goyal, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. (20th June 2018) Authors: Meric-Bernstam, F; Arkenau, H; Tran, B; Bahleda, R; Kelley, R; Hierro, C; Ahn, D; Zhu, A; Javle, M; Winkler, R; He, H; Huang, J; Goyal, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients. (15th June 2017) Authors: Kavanaugh, A; Aa, A Van der; Jamoul, C; Li, W; Goyal, L; Pan, Y; Harrison, P; Tasset, C; Tarrant, J; Galien, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0205 Effects of the jak1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate. (15th June 2017) Authors: Genovese, MC; Li, W; Goyal, L; Pan, Y; Aa, A Van der; Jamoul, C; Harrison, P; Tasset, C; Galien, R; Tarrant, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn's disease. (8th June 2018) Authors: Keshav, Satish; Roblin, X; D'Haens, G; Galien, R; Goyal, L; Li, W; Mirza, A; Serone, A; Tasset, C; Van der Aa, A; Woo, J; Vermeire, S Journal: Gut Issue: Volume 67(2018)Supplement 1 Page Start: A63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients. (15th June 2017) Authors: Taylor, P; Westhovens, R; Aa, A Van der; Jamoul, C; Li, W; Goyal, L; Pan, Y; Harrison, P; Tasset, C; Tarrant, J; Galien, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗